Use of Nuclear Factor Erythroid 2-Eelated Factor Activators as A Strategy to Improve the Side Effects of COVID-19

Coronavirus disease19 (COVID19) is a new member of the coronavirus family causing acute respiratory infection. Patients with COVID19 have a higher risk of developing oxidative stress during this infection. Moreover, the virus induces ROS production that activates cellular pathways for viral replication. Nuclear factor erythroid 2related factor (Nrf2) is a crucial transcription factor in cellular antioxidant defense by mediating Virusinduced oxidative stress and ROS production. This article suggests that an Nrf2 activator may be beneficial in preventing oxidative stress development in COVID19 patients. Coronaviruses are a significant group of viruses that cause different illnesses in humans and animals. These illnesses can range from the common cold to more severe diseases such as SARS (Severe acute respiratory syndrome), Middle East Respiratory Syndrome (MERS), and COVID19. COVID19 is a new viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2). The main symptoms of COVID19infected patients are fever, dry cough, fatigue, and sometimes respiratory problems such as shortness of breath, sore throat, and infection [1].